New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - leflunomide 10mg - film coated tablet - 10 mg - active: leflunomide 10mg excipient: colloidal silicon dioxide crospovidone hypromellose lactose monohydrate macrogol 8000 magnesium stearate maize starch povidone purified talc titanium dioxide - arava is indicated for the treatment of: · rheumatoid arthritis, to improve signs and symptoms to retard joint destruction and to improve functional ability and quality of life. leflunomide may be used in patients who have failed to respond to other treatments or as a first line of treatment in patients who have a contraindication to other treatments. · active psoriatic arthritis. arava is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - leflunomide, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; povidone; colloidal anhydrous silica; magnesium stearate; crospovidone; hypromellose; macrogol 8000; titanium dioxide; purified talc - arava is indicated for the treatment of: active rheumatoid arthritis. active psoriatic arthritis. arava is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of arava with other disease modifying anti-rheumatic drugs (dmards) has not been adequately studied (see precautions).

Israel - English - Ministry of Health

sanofi israel ltd - leflunomide - film coated tablets - leflunomide 10 mg - leflunomide - leflunomide - arava is indicated in adults for the treatment of active rheumatoid arthritis (ra) : 1. to reduce signs and symptoms 2. to inhibit structural damage as evidenced by x-ray erosions and joint space narrowing 3. to imptove physical function. arava is indicated for the treatment of adult patients with active psoriatic arthritis.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - leflunomide 100mg - film coated tablet - 100 mg - active: leflunomide 100mg excipient: colloidal silicon dioxide crospovidone hypromellose lactose monohydrate macrogol 8000 magnesium stearate maize starch povidone purified talc titanium dioxide - arava is indicated for the treatment of: · rheumatoid arthritis, to improve signs and symptoms to retard joint destruction and to improve functional ability and quality of life. leflunomide may be used in patients who have failed to respond to other treatments or as a first line of treatment in patients who have a contraindication to other treatments. · active psoriatic arthritis. arava is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - leflunomide 20mg - film coated tablet - 20 mg - active: leflunomide 20mg excipient: colloidal silicon dioxide crospovidone hypromellose iron oxide yellow lactose monohydrate macrogol 8000 magnesium stearate maize starch povidone purified talc titanium dioxide - arava is indicated for the treatment of: · rheumatoid arthritis, to improve signs and symptoms to retard joint destruction and to improve functional ability and quality of life. leflunomide may be used in patients who have failed to respond to other treatments or as a first line of treatment in patients who have a contraindication to other treatments. · active psoriatic arthritis. arava is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - leflunomide, quantity: 20 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; povidone; colloidal anhydrous silica; magnesium stearate; crospovidone; hypromellose; macrogol 8000; titanium dioxide; purified talc; iron oxide yellow - arava is indicated for the treatment of: active rheumatoid arthritis. active psoriatic arthritis. arava is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of arava with other disease modifying anti-rheumatic drugs (dmards) has not been adequately studied (see precautions).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - leflunomide - tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - leflunomide - tablet - 10mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi-aventis, germany - leflunomide - film-coated tablet - 10 mg

Israel - English - Ministry of Health

sanofi israel ltd - leflunomide - film coated tablets - leflunomide 20 mg - leflunomide - leflunomide - arava is indicated in adults for the treatment of active rheumatoid arthritis (ra) : 1. to reduce signs and symptoms 2. to inhibit structural damage as evidenced by x-ray erosions and joint space narrowing 3. to imptove physical function. arava is indicated for the treatment of adult patients with active psoriatic arthritis.